Frank Reed

A new program aims to tackle soaring health costs by offering employer-sponsored access to popular weight-loss drugs, potentially expanding access while curbing expenses.

Amid ongoing drug shortages, Phlow Corp. is advocating for a stronger domestic pharmaceutical supply chain. CEO Dr. Eric Edwards testified before Congress, highlighting the need for resilience and innovation in American medicine.

A new weight loss supplement promising rapid results is drawing skepticism as questions emerge regarding its clinical validation, company registration, and scientific backing. Is this a breakthrough or buyer beware?

A potential new FDA initiative aims to drastically reduce response times to drug sponsors, but details remain unconfirmed. Is this a sign of a changing regulatory landscape?

A leading materials science company unveils a potential breakthrough in tire technology, offering an alternative to a chemical linked to the deaths of coho salmon and other aquatic life. The innovation faces regulatory hurdles and competition.

European regulators endorse a novel pertussis vaccine, offering a targeted approach to bolster immunity and address waning protection against the highly contagious respiratory illness.

Molecular Designs launches a new multiplex PCR panel designed to accelerate HPV research, offering improved efficiency and accuracy for scientists studying cancer prevention and treatment.

The FDA's approval of POHERDY marks a significant step forward in affordable cancer care, introducing the first biosimilar alternative to PERJETA for HER2-positive breast cancer patients.

A promising higher dose of Biogen’s SMA therapy, Spinraza, hit a snag with the FDA, despite positive trial data. The company navigates a crowded market with rivals innovating gene therapies and oral treatments.

Direct-to-consumer epigenetic testing is booming, promising insights into biological age and health risks. But experts raise questions about accuracy, interpretation, and whether the science truly delivers on its promises.

A new direct-to-consumer epigenetic test aims to map aging at the organ level. We investigate the science, the cost, and the implications for the burgeoning longevity market.